Research programme: apolipoprotein A-I stimulants - KineMed

Drug Profile

Research programme: apolipoprotein A-I stimulants - KineMed

Alternative Names: Acute HDL therapeutic - KineMed; Apo-A1 mimetic peptide for atherosclerosis - KineMed; ApoA-I mimetic lead compound for atherosclerosis and heart disease - KineMed; FX-5A

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator KineMed
  • Class Peptides
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Atherosclerosis; Cardiovascular disorders

Highest Development Phases

  • No development reported Atherosclerosis; Cardiovascular disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (IV)
  • 11 Apr 2012 Research programme: apolipoprotein A-I stimulants - KineMed is available for licensing as of 11 Apr 2012. http://www.kinemed.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top